Regorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer. A randomised, phase 3 clinical trial is planned.
Regorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer. A randomised, phase 3 clinical trial is planned.
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy